Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial
| Autor: | Sherry Cao, Julie Doostzadeh, Krishnankutty Sudhir, Robert J. Applegate, Xiaolu Su, James B. Hermiller, Charles A. Simonton, Paul C. Gordon, Alexandra J. Lansky, Jerome Williams, Gregg W. Stone |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Paclitaxel medicine.medical_treatment Myocardial Infarction Coronary Artery Disease Kaplan-Meier Estimate Coronary Angiography Prosthesis Design Risk Assessment Severity of Illness Index Coronary artery disease Necrosis Risk Factors Angioplasty medicine Creatine Kinase MB Form Humans Radiology Nuclear Medicine and imaging Single-Blind Method Myocardial infarction Everolimus Prospective Studies Angioplasty Balloon Coronary Aged Sirolimus business.industry Myocardium Stent Cardiovascular Agents Drug-Eluting Stents General Medicine Middle Aged medicine.disease United States Surgery Treatment Outcome Drug-eluting stent Cardiovascular agent Female Cardiology and Cardiovascular Medicine business Mace Biomarkers medicine.drug |
| Zdroj: | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions. 76(5) |
| ISSN: | 1522-726X |
| Popis: | To evaluate whether an everolimus-eluting stent (EES) with thinner stent struts and polymer results in less periprocedural myonecrosis and adverse outcomes.Higher periprocedural myocardial infarction (MI) rates have been reported with the TAXUS® EXPRESS(2) paclitaxel-eluting stent (PES) compared to the bare metal EXPRESS(2)® stent due to more frequent side branch compromise, presumably attributable to the thickness of the stent/polymer on the PES.In the SPIRIT III trial, we identified 113 patients in the XIENCE V® EES group and 63 patients in the TAXUS EXPRESS(2) PES group who met the criteria of having a lesion with a jailed side branch (2 mm diameter, and50% stenosis). Two-year clinical outcomes were evaluated.A periprocedural increase in Creatine Kinase-MB1× upper normal level occurred in 9.0% of EES compared to 29.7% of PES patients with jailed side branches, P = 0.01. Through 2 years, major adverse cardiac events (MACE; cardiac death, MI, or target lesion revascularization [TLR]) occurred in 6.8% of EES and 19.0% of PES jailed side branch patients (P = 0.03), with numerically lower rates of MI (2.9% vs. 10.3%, P = 0.07) and TLR (3.9% vs. 10.3%, P = 0.17) in the EES group, with comparable rates of cardiac death (1.9% vs. 1.7%, P = 1.00).In this post-hoc analysis of the SPIRIT III RCT, patients undergoing stenting of target lesions with jailed side branches with the thin strut and polymer XIENCE V EES compared to the thicker strut TAXUS PES had lower rates of MACE through 2 years due to fewer MIs and TLRs. © 2010 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text